

CITATION REPORT

List of articles citing

Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance

DOI: 10.18632/oncotarget.9539
Oncotarget, 2016, 7, 39931-39944.

Source: <https://exaly.com/paper-pdf/87801735/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
59	Epigenetic regulation of epithelial-mesenchymal transition. <i>Cellular and Molecular Life Sciences</i> , 2016 , 73, 4493-4515	10.3	73
58	KDM5 lysine demethylases are involved in maintenance of 3'UTR length. <i>Science Advances</i> , 2016 , 2, e1501662	16.2	16
57	An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting. <i>Nucleic Acids Research</i> , 2016 , 44, e149	20.1	122
56	Molecular and Cellular Changes During Cancer Progression Resulting From Genetic and Epigenetic Alterations. <i>Progress in Molecular Biology and Translational Science</i> , 2016 , 144, 3-47	4	17
55	Epigenetic regulation of RTK signaling. <i>Journal of Molecular Medicine</i> , 2017 , 95, 791-798	5.5	12
54	Novel targets in the treatment of neuroendocrine tumors: RBP2. <i>International Journal of Endocrine Oncology</i> , 2017 , 4, 31-41	0.3	0
53	Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations. <i>Trends in Cancer</i> , 2017 , 3, 631-642	12.5	12
52	JARID1 Histone Demethylases: Emerging Targets in Cancer. <i>Trends in Cancer</i> , 2017 , 3, 713-725	12.5	43
51	The Molecular Basis of Histone Demethylation. <i>Cancer Drug Discovery and Development</i> , 2017 , 151-219	0.3	6
50	miR-27a induced by colon cancer cells in HLECs promotes lymphangiogenesis by targeting SMAD4. <i>PLoS ONE</i> , 2017 , 12, e0186718	3.7	26
49	Small molecule KDM4s inhibitors as anti-cancer agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018 , 33, 777-793	5.6	14
48	Profiling plasma extracellular vesicle by pluronic block-copolymer based enrichment method unveils features associated with breast cancer aggression, metastasis and invasion. <i>Journal of Extracellular Vesicles</i> , 2018 , 7, 1458574	16.4	14
47	Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view. <i>Leukemia Research</i> , 2018 , 68, 105-111	2.7	17
46	Autochthonous tumors driven by loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3741-E3748	11.5	6
45	Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	35
44	Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. <i>Oncotarget</i> , 2018 , 9, 8985-8998	3.3	3
43	Acquired Resistance to Drugs Targeting Tyrosine Kinases. <i>Advances in Cancer Research</i> , 2018 , 138, 71-98	5.9	35

42	Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1. <i>Molecular Cancer Research</i> , 2018 , 16, 1458-1469	6.6	38
41	Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges. <i>Computational and Structural Biotechnology Journal</i> , 2018 , 16, 211-223	6.8	34
40	KDM5 histone demethylases repress immune response via suppression of STING. <i>PLoS Biology</i> , 2018 , 16, e2006134	9.7	54
39	Identification of ryuvidine as a KDM5A inhibitor. <i>Scientific Reports</i> , 2019 , 9, 9952	4.9	11
38	Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines. <i>Cancers</i> , 2019 , 11,	6.6	24
37	The molecular landscape of histone lysine methyltransferases and demethylases in non-small cell lung cancer. <i>International Journal of Medical Sciences</i> , 2019 , 16, 922-930	3.7	7
36	Pharmacoepigentic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigentics, and Nutriepigentics. 2019 , 191-424		6
35	Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B. <i>Molecules</i> , 2019 , 24,	4.8	15
34	The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 138, 132-138	7	6
33	Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers. <i>Bioorganic Chemistry</i> , 2019 , 88, 102929	5.1	20
32	Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction. <i>Scientific Reports</i> , 2019 , 9, 3179	4.9	22
31	Intratumoral Heterogeneity: More Than Just Mutations. <i>Trends in Cell Biology</i> , 2019 , 29, 569-579	18.3	103
30	JmjC-domain-Containing Histone Demethylases. <i>Methods and Principles in Medicinal Chemistry</i> , 2019 , 263-296	0.4	
29	. <i>Methods and Principles in Medicinal Chemistry</i> , 2019 ,	0.4	1
28	KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 706-717	6.1	22
27	The great escape: tumour cell plasticity in resistance to targeted therapy. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 39-56	64.1	169
26	Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition. <i>Cancer Research</i> , 2020 , 80, 524-535	10.1	16
25	Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 223	12.8	25

24	Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. <i>Blood</i> , 2020 , 136, 2275-2289	2.2	21
23	Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	14
22	Inactivation of Epigenetic Regulators due to Mutations in Solid Tumors. <i>Biochemistry (Moscow)</i> , 2020 , 85, 735-748	2.9	0
21	Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 129, 110392	7.5	9
20	Histone methylation can either promote or reduce cellular radiosensitivity by regulating DNA repair pathways. <i>Mutation Research - Reviews in Mutation Research</i> , 2021 , 787, 108362	7	0
19	The emerging role of KDM5A in human cancer. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 30	22.4	11
18	KDM5A silencing transcriptionally suppresses the FXD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 4040-4052	5.6	4
17	Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy. <i>Scientific Reports</i> , 2021 , 11, 7259	4.9	5
16	Role of Nitric Oxide in Gene Expression Regulation during Cancer: Epigenetic Modifications and Non-Coding RNAs. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
15	Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 736935	5.7	4
14	Pharmacological inhibition of KDM5A for cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2021 , 226, 113855	6.8	5
13	Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. <i>Seminars in Cancer Biology</i> , 2020 ,	12.7	6
12	CECR2 Drives Breast Cancer Metastasis by Suppressing Macrophage Inflammatory Responses.		2
11	Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. <i>Oncotarget</i> , 2017 , 8, 34896-34910	3.3	29
10	The role of histone lysine demethylases in cancer cells resistance to tyrosine kinase inhibitors.. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019 , 2, 326-334	4.5	1
9	A computer aided drug discovery based discovery of lead-like compounds against KDM5A for cancers using pharmacophore modeling and high-throughput virtual screening. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021 ,	4.2	2
8	KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. <i>Frontiers in Oncology</i> , 2021 , 11, 750315	5.3	2
7	CECR2 drives breast cancer metastasis by promoting NF- κ B signaling and macrophage-mediated immune suppression.. <i>Science Translational Medicine</i> , 2022 , 14, eabf5473	17.5	3

6	Role of Histone Methylation in Cancer: Pathobiology & Therapeutics. 2022 , 1-18	
5	Role of Histone Methylation in Cancer: Pathobiology and Therapeutics. 2022 , 1411-1428	0
4	JMJD family proteins in cancer and inflammation. 2022 , 7,	2
3	Targeting epigenetic regulators to overcome drug resistance in cancers. 2023 , 8,	2
2	The role and prospect of lysine-specific demethylases in cancer chemoresistance.	0
1	Knockdown of KDM5B Leads to DNA Damage and Cell Cycle Arrest in Granulosa Cells via MTF1. 2023 , 45, 3219-3237	0